VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr, +17

New England Journal of Medicine

A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis

Geraint B. Rogers, Nur Masirah M. Zain, Kenneth D. Bruce, +5

Annals of the American Thoracic Society

The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial

Geraint B. Rogers, Kenneth D. Bruce, Megan Martin, +2

The Lancet Respiratory Medicine

Respiratory Microbiota CompositionNon-cystic Fibrosis BronchiectasisPlacebo-controlled Bless TrialInfectious Respiratory DiseasePulmonary Fibrosis +6

<i>R</i><i>othia mucilaginosa</i>is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease

Charlotte Rigauts, Juliana Aizawa, Steven Taylor, +18

European Respiratory Journal

Airway Mucus Hyperconcentration in Non–Cystic Fibrosis Bronchiectasis

Kathryn Ramsey, Alice C.–H. Chen, Giorgia Radicioni, +22

American Journal of Respiratory and Critical Care Medicine

Matrix Metalloproteinases Vary with Airway Microbiota Composition and Lung Function in Non–Cystic Fibrosis Bronchiectasis

Steven Taylor, Geraint B. Rogers, Alice C.–H. Chen, +3

Annals of the American Thoracic Society

Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry

S. Visser, Peter T.P. Bye, Greg J. Fox, +11

Respiratory Medicine

AsthmaAustralian AdultsPulmonary CareRespiratory InfectionPulmonary Disease +5

Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut

Yanan Wang, Lex E. X. Leong, Rebecca Keating, +8

Gut Microbes

Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma

Rhiannon B. Werder, Md Ashik Ullah, Muhammed Mahfuzur Rahman, +24

American Journal of Respiratory and Critical Care Medicine

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

Ahmet Uluer, Gordon MacGregor, Pilar Azevedo, +101

The Lancet Respiratory Medicine

MedicinePhase 2